Welcome to our dedicated page for Clarivate news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate stock.
Clarivate Plc reports developments in data, analytics and workflow software for academia and government, intellectual property, and life sciences and healthcare. Its news commonly covers earnings, subscription and recurring revenue trends, cash flow and leverage actions, and progress under its operating improvement initiatives.
Company updates also focus on AI-enabled research and decision-support products, including Web of Science Research Intelligence, Nexus Connect, Cortellis Regulatory Intelligence, Derwent-based patent analytics and other Clarivate data assets. Recurring announcements address institutional research intelligence, academic library workflows, regulatory intelligence for life sciences teams, intellectual property benchmarks and investor conference appearances.
Clarivate (NYSE: CLVT) announced the adoption of a Tax Benefits Preservation Plan to safeguard its U.S. net operating loss carryforwards exceeding $1 billion as of September 30, 2022. This plan aims to prevent an 'ownership change' that could limit its ability to utilize these tax benefits. The plan will expire on October 31, 2023, unless terminated earlier. Shareholders will receive one preferred share purchase right for each ordinary share, activating if any party acquires 4.9% or more of shares. The plan is similar to those by other companies with significant NOLs.
Clarivate Plc (NYSE: CLVT) announced a reduction in its Board of Directors from 14 to 11 members, with the resignation of directors Balakrishnan S. Iyer, Kosty Gilis, and Roxane White. This move aims to enhance corporate governance, with 10 of the 11 remaining directors being independent and 45% being female or racially diverse. Board Chair Andrew Snyder emphasized that a smaller board will improve decision-making efficiency and focus on long-term growth and shareholder value.
Clarivate Plc (NYSE: CLVT) announced on December 6, 2022, the integration of linked specialty pharmacy claims data into its real-world data solutions. This new U.S. dataset enhances the company's offerings by providing insights into high-cost medications and the treatment journeys of patients with chronic and rare diseases. Specialty drugs comprise over 20% of the market in these areas. The dataset covers more than 500 specialty drugs and is updated weekly, enabling robust analytics and improved patient outcome strategies.
Clarivate Plc (NYSE: CLVT), a leader in providing insights to enhance innovation, announced that CEO Jonathan Gear and CFO Jonathan Collins will present at the Barclays Global Technology, Media, and Telecommunications Conference on December 7, 2022, at 10:25 AM PT (1:25 PM ET). Attendees can access the live webcast here, and it will be available for replay. Clarivate aims to assist customers in transforming innovations into real-world solutions.
Clarivate Plc (NYSE:CLVT) has launched its annual report, The Annual G20 Scorecard – Research Performance 2022, showcasing the research performance of G20 nations. Published by the Institute for Scientific Information, the report is timed with the G20 Summit in Bali. Key findings reveal that Australia maintains the highest international impact, while China's output has tripled. Saudi Arabia sees significant international collaboration, and South Korea leads in research expenditure. The UK and US demonstrate strong research impacts, with a notable focus on domestic and collaborative work.
On November 16, 2022, Clarivate Plc (NYSE: CLVT) announced a strategic partnership with IPwe Inc. to lead the digital transformation of intellectual property through advanced blockchain technology and AI. This collaboration aims to combine Clarivate's patent data with IPwe's Smart Intangible Asset Management platform, enhancing the validation and management of patent portfolios. By tokenizing patents, IPwe seeks to improve transparency and reduce transaction friction in the IP market. This partnership is expected to provide customers with a data-driven approach to managing intangible assets.
Clarivate Plc (NYSE: CLVT) announced the 2022 list of Highly Cited Researchers, recognizing 6,938 researchers worldwide for significant contributions across various fields. The U.S. leads with 2,764 researchers but has seen a gradual decrease in share since 2018. Mainland China is rapidly closing the gap, now with 1,169 researchers. Clarivate has enhanced its analysis to prevent research misconduct, ensuring the list reflects genuine influence. Notable findings include 7,225 total awards across disciplines, highlighting the global diversity of research excellence.
On November 9, 2022, Clarivate Plc (NYSE: CLVT) announced that CEO Jonathan Gear and CFO Jonathan Collins will present at the RBC Capital Markets 2022 Technology, Internet, Media and Telecommunications Conference on November 15, 2022, at 1:25 PM Eastern Time. A live webcast of the presentation will be available here and can be replayed later. Clarivate specializes in information and insights to expedite innovation across various sectors.
On November 8, 2022, Clarivate Plc (NYSE: CLVT; CLVT PR A) declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares. This dividend is payable in cash on December 1, 2022 to shareholders recorded as of the close of business on November 15, 2022. Clarivate continues to affirm its commitment to delivering value to its shareholders through consistent dividend payments.
Clarivate reported Q3 2022 revenues of $635.7 million, marking a 43.8% increase, driven by the acquisition of ProQuest. However, a significant non-cash goodwill impairment led to a net loss of $4,434.4 million, with a net loss per share of $6.64. Organic revenue growth was 1.2%, with subscription revenues rising 65.6%, but transactional revenues declined 9.4%. Adjusted net income was $143.7 million, up 26.5%. The company generated $372.4 million in cash from operations.